Introduction c-Jun NH2-terminal kinases (JNKs) are strongly activated by various cellular stresses, such as ultraviolet irradiation and oxidative stress, which induce apoptosis or growth inhibition (Hamdi et al., 2005; Deng et al., 2006) . JNK is considered as 'stress-activated protein kinase' and plays an essential role in inflammation and apoptosis (Xia et al., 1995) . The target proteins of JNK have the transcription factor c-Jun, which is phosphorylated and activated by JNK, forkhead transcriptional factor, which is phosphorylated by JNK and then translocates to the nucleus for regulating the transcription of some target genes, and some pro-apoptotic or antiapoptotic proteins such as Bax and Bcl-2 (Zhang et al., 1996; Kops et al., 2002) .
Autophagy is an evolutionarily conserved proteindegradation pathway in eukaryotes that is essential for cell survival under nutrient-limiting conditions (Bursch, 2001 ; Levine and Klionsky, 2004) . During autophagy, portions of the cytoplasm are sequestered by doublemembrane vesicles called autophagosomes and are degraded after fusion with lysosomes for subsequent recycling (Degenhardt et al., 2006; Levine, 2007) . There is now evidence for the role of autophagy during development (Baehrecke, 2003; Melendez et al., 2003; Otto et al., 2003) , in life-span extension (Bergamini et al., 2003; Melendez et al., 2003) , and in diseases such as cancer (Ogier-Denis and Codogno, 2003; Furuya et al., 2005) , neurodegenerative disease (Larsen and Sulzer, 2002; Yuan et al., 2003) and myopathies (Saftig et al., 2001; Nishino, 2003) . In addition, the cytotoxicity of some anticancer agents is associated with the induction of autophagy (Kondo et al., 2005; Cao et al., 2007; Ertmer et al., 2007) . At the early stage of tumour development, autophagy functions as a tumour suppressor and many cancer cells undergo autophagic cell death after cancer therapies. By contrast, at advanced stages of tumour development, cancer cells that are located in the central areas of the tumour are poorly vascularized, so the induction of autophagy allows them to survive in these low-nutrient and low-oxygen conditions (Cuervo, 2004) . Autophagy protects some cancer cells against anticancer treatments by blocking the apoptotic pathway ('protective autophagy').
A number of signalling pathways are involved in the regulation of autophagy. Recent discoveries of mammalian orthologues of yeast-signalling intermediates have offered significant insights into the underlying pathways. The stimulation of the class I PI3K/PKB signalling pathway by growth factors and cytokines has an inhibitory effect on autophagy in many cell types (Petiot et al., 2000; Arico et al., 2001; Melendez et al., 2003; Kanzawa et al., 2004) . This inhibitory effect is probably due to the class I PI3K/PKB-dependent activation of the kinase target of rapamycin, which downregulates autophagy (Blommaart et al., 1995; Noda and Ohsumi, 1998; Abeliovich et al., 2000) . The suppression of autophagic cell death by caspase-8 in mammalian cells indicated that caspases can regulate both apoptotic and non-apoptotic cell death (Yu et al., 2004) . JNK activation mediated by IRE1 in the early phase of the endoplasmic reticulum stress is required for autophagosome formation (Ogata et al., 2006) , but how JNK activation induces autophagy and whether anticancer agent-induced autophagy is dependent upon JNK activation remain to be elucidated.
Beclin 1 (orthologue of yeast Atg6), the first identified mammalian autophagy protein (Liang et al., 1999) , can function as a tumour suppressor in mammals. The Beclin 1 protein could play a role in recruiting proteins from the cytosol for autophagic degradation or in supplying the autophagic pathway with membrane components (Kihara et al., 2001) . The expression of Beclin 1 correlates directly with autophagosome formation and is reduced in a large majority of breast and ovarian cancers (Liang et al., 1999; Yue et al., 2003) . In addition to interacting with class III PI3K, Beclin 1 is able to bind Bcl-2 family members, Bcl-2 and Bcl-xL (Liang et al., 1999 (Liang et al., , 2001 . The induction of Beclin 1 expression can be found during autophagy in various cell types (Chu et al., 2007) . But how Beclin 1 expression is regulated in autophagic cell death remains elusive.
Ceramide acts as a second messenger in the signal transduction pathway activated by a host of stress agents (Kim et al., 1991) , ionizing radiation (HaimovitzFriedman et al., 1994) and platelet-activating factor and so on (Goggel et al., 2004) . Ceramide-mediated apoptotic cell death has been extensively investigated (Obeid et al., 1993; Cifone et al., 1994; Verheij et al., 1996 ). An earlier study shows that ceramide initiates apoptosis through the SAPK/JNK cascade (Verheij et al., 1996) . However, several investigations indicate that nonapoptotic cell death is induced in certain tumour or normal cells by ceramide (Mengubas et al., 1999; Gewies et al., 2000; Mochizuki et al., 2002; Daido et al., 2004; Kim et al., 2005) . It is also reported that ceramide could induce autophagy by interfering with class I PI3K signalling pathway and increasing the expression of Beclin 1 (Scarlatti et al., 2004) . Therefore, we explore the relationship between JNK pathway activation and Beclin 1 expression in ceramide-induced autophagy.
In this study, we focus on the relationships among activation of JNK pathway, Beclin 1 expression and autophagy induction. We demonstrated that during autophagy, JNK pathway was activated in cancer cell lines, which also resulted in an increased Beclin 1 expression. JNK-specific inhibitor SP600125 or small interfering RNAs (siRNAs) targeting JNK1/2 or c-Jun could inhibit Beclin 1 upregulation and autophagy induction. Furthermore, c-Jun was directly involved in the regulation of beclin 1 transcription in response to ceramide treatment. These data provide a novel mechanism for the regulation of Beclin 1 expression in anticancer agents-induced autophagy.
Results
Ceramide-induced caspase-3-independent cell death in Hep3B and CNE2 cells We initially determined whether ceramide could induce cancer cell death by the vital dye trypan blue staining ( Figure 1a ). Ceramide was appropriately applied at a concentration ranging from 0 to 50 mM. Following ceramide treatment for 24 h, the number of dead cancer cells increased in a concentration-dependent manner. To determine whether the cell death was caspase-3-dependent, we first detected the cleavage of caspase-3, which is an executive component of the caspase pathway. Using immunoblotting analysis, we could not detect the cleavage of caspase-3 in both cancer cells at all time points or concentrations following treatment with ceramide. Dihydroceramide (DH-ceramide) was used as a negative control in studies of ceramide (Huwiler et al., 2004) . Then, we detected the cleavage of PARP, a mediator of apoptosis. Concordantly, the cleavage of PARP was also undetectable (Figure 1b) . These results indicated that ceramide induced caspase-3-independent cell death in Hep3B and CNE2 cells. To further confirm that ceramide induced mainly non-apoptotic cell death, Hep3B and CNE2 cells exposed to various concentrations ceramide were analysed at indicated times by flow cytometry. As shown in Figure 1c , apoptotic rates were quite low in both cancer cells after treatment. Combined with the results from trypan blue assay above, it suggested that ceramide induced mainly non-apoptotic cell death.
Induction of autophagy was required for ceramide-mediated cell death Earlier studies showed that fluorescent labelling of marker proteins, such as Atg5, LC3 and Atg7, in combination with fluorescent and non-fluorescent dyes specific for acidic compartments and lysosomes, such as acridine orange (AO) and monodansylcadaverine (MDC), has allowed visualization of the steps involved in autophagosome formation (Mizushima, 2004) . In our study, to examine whether ceramide could induce autophagy, the cancer cells were treated with 20 mM ceramide for 24 h. We found that the punctate dots of LC3 were detectable in the cytoplasm by indirect immunofluorescence (Figure 2a) , which indicated the association of LC3 with autophagosomal membranes following ceramide treatment. Furthermore, the development of acidic vesicular organelles was detected. CNE2 and Hep3B cells were stained with acridine orange as described in Materials and methods. The results showed that an abundant cytoplasmic acidic vesicular organelle formation, which is characteristic of autophagy, was observed in ceramide-treated cells, whereas the untreated cancer cells exhibited no obvious cytoplasmic staining ( Figure 2a ). As MDC accumulates in mature autophagic vacuoles, such as autophagolysosomes, MDC staining can be used to detect autophagic vacuoles. As shown in Figure 2a , in both cancer cells treated with ceramide, the accumulation of MDC was noticeable, whereas in untreated cancer cells, MDClabelled cells were almost undetectable ( Figure 2a ). The amount of phosphatidylethanolamine (PE)-conjugated form of LC3 (LC3-II) correlates well with the number of autophagosomes (Kabeya et al., 2000) . Using immunoblotting analysis, we observed a clear increase in LC3-II in a dose-and time-dependent manner in Hep3B and CNE2 cells following ceramide treatment (Figure 2b ).
To further confirm that ceramide induced autophagic cell death, the Hep3B cells were treated with 20 mM ceramide and/or 10 mM 3-methyladenine (3-MA), an inhibitor of PI3K, commonly used for the specific inhibition of autophagosome formation (Seglen and Bohley, 1992) . In light microscope, we observed that under ceramide treatment, most of the Hep3B cells appeared round, some were detached from the surface of wells and the number of cells was reduced, but the effects by ceramide induction were reversed when the cells were in parallel treated with 3-MA and the decrease of viable cell number could be effectively suppressed by 3-MA (Figure 2c ). Meanwhile, 3-MA also inhibited the formation of LC3-II induced by ceramide in both Hep3B and CNE2 cells in immunoblotting analysis (Figure 2d ). These data collectively argued for the induction of autophagy by ceramide in the Hep3B and CNE2 cells.
Ceramide-induced phosphorylation of JNK and c-Jun
Sphingolipids are known to activate mitogen-activated protein kinase signalling pathways in a variety of cell types. To study the role of SAPK/JNK signalling pathway in autophagy induced by ceramide, first of all, activation of JNK signal pathway by ceramide was detected. As shown in Figures 3a and b , ceramide stimulated the phosphorylation of JNK in a dose-and time-dependent manner in both cell lines. Furthermore, ceramide also increased phosphorylation of the JNK substrate c-Jun (Figures 3a and b) .
Upregulation of Beclin 1 expression following ceramide treatment To determine whether Beclin 1 expression would be upregulated in CNE2 and Hep3B cells exposed to ceramide, the expression levels of Beclin 1 mRNA and protein were detected. We treated the cells with concentrations of ceramide varying from 6.25 to 50 mM. After treatment for 24 h, reverse transcription PCR (RT-PCR) analysis revealed an upregulation of Beclin 1. With increasing concentrations of ceramide, an increasing amount of Beclin 1 was detected (Figure 3c ). With immunoblotting analysis, the results showed that Beclin 1 protein expression also increased dose-and time-dependently in the cells exposed to ceramide (Figure 3d ).
JNK-specific inhibitor SP600125 blocked autophagy and upregulation of Beclin 1 expression induced by ceramide
To further investigate the role of JNK in ceramidemediated autophagy, cells were pretreated with 10 mM of SP600125 (a JNK activity-specific inhibitor) for 1 h and then exposed to 20 mM ceramide. As shown in Figure 4a , the MDC-labelled cells decreased after pretreatment with SP600125 in CNE2 cells. In contrast to ceramide treatment only, pretreatment with SP600125 decreased the punctate dots of LC3 in the cytoplasm (Figure 4a) . Furthermore, SP600125 treatment blocked the increase of LC3-II induced by ceramide (Figure 4c ). These results indicated that the JNK-specific inhibitor could block ceramide-induced autophagy.
To determine whether the activation of JNK is required for Beclin 1 expression in autophagy elicited by ceramide, the cells were pretreated with SP600125 for 1 h and then exposed to ceramide. As shown in Figure 4b , the upregulation of Beclin 1 mRNA levels was obviously inhibited by SP600125 in both cancer cell lines. Furthermore, the phosphorylation level of c-Jun and the upregulation of Beclin 1 protein expression induced by ceramide were also blocked by SP600125 (Figure 4c ).
Silencing of JNK1/2 by siRNA blocked induction of Beclin 1 expression To further determine whether activation of JNK was required for Beclin 1 expression during autophagy, an additional approach, siRNA directed against a common sequence of JNK1/2, was used to knock down JNK expression. Figure 5a showed that transient transfection with this siRNA led to the downregulation of JNK. The induction of LC3-II by ceramide was inhibited by silencing of JNK (Figure 5a ). More importantly, the downregulation of JNK by siRNA not only efficiently inhibited the phosphorylation level of c-Jun but also prevented the upregulation of Beclin 1 protein and mRNA expression induced by ceramide in both cancer cells (Figures 5a and b) . (Figure 6a ). Sequence analysis detected a perfect c-Jun-binding site (TGACCTCA) within the beclin 1 promoter (À302 to À310 from the translation-initiation site within the first exon of human beclin 1). Chromatin immunoprecipitation (ChIP) assay was employed to analyse c-Jun binding to the beclin 1 promoter. The result reveals that binding of c-Jun to beclin 1 promoter does increase substantially following ceramide treatment (Figure 6b) . We also generated a luciferase reporter construct containing 2245 bp from the promoter of beclin 1 and transfected this construct to cancer cells with or without ceramide treatment. The results showed the upregulation of luciferase activity following ceramide treatment (Figure 6c ). The luciferase reporter constructs containing the c-Jun-binding-conserved sequence from beclin 1 promoter or its mutant were constructed and transfected to cancer cells. The results showed that the luciferase activity of the construct with wild type of c-Jun-bindingconserved sequence obviously increased, but the construct with the mutant sequence abolished the induction of luciferase activity by ceramide (Figure 6d ). These findings suggested that c-Jun could be directly involved in the beclin 1 transcription after ceramide treatment.
Knockdown of Beclin 1 by siRNA blocked ceramide-mediated autophagy To exploit whether Beclin 1 plays an intrinsic role in autophagy induced by ceramide, the effect of Beclin 1 knockdown on ceramide-mediated autophagic cell death was investigated. First, two different siRNAs were designed to downregulate the expression of Beclin 1 (Figure 7a ). Silencing of Beclin 1 in Hep3B cells significantly blocked LC3-II induction by ceramide (Figure 7b ). After Beclin 1 knockdown by siRNA, Hep3B cells exhibited less MDC-labelled compared with control siRNA-treated cells following ceramide treatment (Figure 7c ). Ceramide could induce autophagic cell death, the dead cells appeared to be round and detached, but siRNA targeting Beclin 1 could rescue Hep3B cells under treatment of ceramide (Figure 7d ). These data suggested that Beclin 1 could play a critical role in determining the autophagic cell death of cancer cells.
Discussion
We reported here that ceramide induced autophagy in human cancer cell lines. Ceramide could also activate JNK pathway and upregulate Beclin 1 expression. Blockage of JNK signalling pathway could inhibit upregulation of Beclin 1 expression. Moreover, the inhibition of JNK pathway and the silencing of Beclin 1 expression could inhibit ceramide-mediated autophagy. c-Jun is directly involved in beclin 1 transcription in response to ceramide. Also, upregulation of Beclin 1 expression by JNK pathway was observed in anticancer drug topotecan-mediated autophagy. These results suggest that anticancer agents can induce autophagy through JNK pathway-mediated Beclin 1 expression.
Earlier, it has been reported that autophagy may be activated by ceramide to affect a caspase-independent cell death (Daido et al., 2004) . Therefore, we established the models of autophagy induced by ceramide or topotecan in cancer cells. In addition, we used DHceramide, an analogue of ceramide, as an inactive ceramide control only, even though a cellular process-the formation of autophagosomes induced by DH-ceramide-has been reported (Zheng et al., 2006) . There is no sufficient evidence that DH-ceramide can induce cell death in human cancer cell lines. Earlier study also demonstrated that DH-ceramide had no effect on JNK phosphorylation (Huwiler et al., 2004) . With MDC staining, acridine orange staining, LC3 immunofluorescence analysis and LC3-II expression examination, we demonstrated that ceramide could induce autophagy in both CNE2 and Hep3B cells. Furthermore, the inhibitor of autophagosome formation, 3-MA, inhibited the cell death caused by ceramide. Therefore, these investigations support a model in which ceramide induces autophagic cell death by the accepted criteria for the establishment of this phenomenon (Zheng et al., 2006) .
Earlier studies on mechanism underlying the regulation of autophagy in cancer cells showed that autophagy was regulated by multiple signalling pathways as diverse as the class III PI3K, and the protein kinases mTOR, extracellular signal-regulated kinase and p38. However, the detailed mechanism by which ceramide acts to induce autophagy or the direct targets of ceramide within the autophagic signalling cascade were still unclear (Zheng et al., 2006) . The initial studies of the role of JNK in apoptotic signals were performed by investigating neutonal cell death (Xia et al., 1995) . JNK pathway is critically involved in both stress-induced and ceramide-induced apoptosis (Verheij et al., 1996) . In IRE1-deficient cells or cells treated with JNK inhibitor, the autophagy induced by endoplasmic reticulum stress was inhibited, indicating that the IRE1-JNK pathway is required for autophagy activation after endoplasmic reticulum stress (Ogata et al., 2006) . These data suggested that in autophagic cell death, activation of the JNK pathway may play a crucial role. In this study, we have demonstrated that ceramide could activate JNK pathway and consequently mediate autophagy. We showed that ceramide enhanced the phosphorylation levels of JNK and c-Jun dose-and time-dependently in both CNE2 and Hep3B cells. Moreover, inhibition of JNK signalling pathway by a specific inhibitor SP600125 or by siRNA could revert the process after ceramide exposure.
Beclin 1 is proposed to function as a tumour suppressor by promoting cellular macroautophagy and also may be an important 'molecular switch' to adjust autophagy and apoptosis in mammalian cells (Wang et al., 2007) . The tumour-suppressing effect of Beclin 1 might be related to a role in regulating autophagic cell death. Our study showed that ceramide enhanced Beclin 1 expression in mRNA and protein levels as demonstrated by reverse transcription PCR and immunoblotting assays, and silencing of Beclin 1 by siRNA blocked ceramide-mediated autophagy, which offered further evidence to support the upregulation of Beclin 1 expression during autophagy.
Although the role of Beclin 1 in class I PI3K/PKB signalling pathway was studied in ceramide-mediated autophagy (Scarlatti et al., 2004) , the direct evidence of the interaction of JNK with this upstream regulator of autophagy remained to lack. Our results showed for the first time that the activation of JNK pathway following ceramide treatment increased expression of Beclin 1, in contrast, blockage of JNK signalling pathway with SP600125 and siRNA targeting JNK1/2 could inhibit upregulation of Beclin 1 expression. These findings suggested that upregulation of Beclin 1 expression during autophagy depended upon JNK pathway. In CNE2 cells, Beclin 1 expression level after pretreatment with JNK-specific inhibitor SP600125 was lower than control. This might be the reason that CNE2 cells have a high basic level of JNK activity, which could initiate a high basic level of Beclin 1 expression.
c-Jun is a predominant target of JNK and can be phosphorylated by JNK and then be activated for regulating the expression of some target genes. Here, we observed that both ceramide-induced c-Jun phosphorylation and Beclin 1 upregulation were blocked by c-Jun siRNA. Also, the binding of c-Jun to beclin 1 promoter increased following ceramide treatment. The results of the luciferase reporter gene assay revealed that the binding of c-Jun to the promoter of beclin 1 could induce gene expression after ceramide treatment. These findings suggested that c-Jun was involved in the regulation of beclin 1 transcription in response to ceramide treatment.
Topotecan, a semisynthetic derivative of camptothecin, is a topoisomerase I inhibitor with well-established antineoplastic properties. Interestingly, we found that this anticancer drug could also induce autophagy in Hep3B cells. Furthermore, the JNK pathway-mediated Beclin 1 expression could also be observed in topotecaninduced autophagy in Hep3B cells (shown in Supplementary information).
Taken together, the results of our study demonstrated that activation of JNK pathway could be involved in the regulation of Beclin 1 expression, and the latter event could be responsible for the induction of autophagic cell death in response to ceramide and topotecan, which not only brings an explanation for the induction of autophagy in response to multiple stresses including anticancer agents but also provides a novel mechanism for the regulation of Beclin 1 expression during autophagy.
Materials and methods
Drugs and reagents N-acetyl-D-sphingosine (ceramide) was purchased from Sigma Co. (St Louis, MO, USA). D-erythro-sphingosine, dihydro-, N-acetyl-(DH-ceramide) were purchased from Calbiochem (Darmstadt, Germany). It was used as a negative control in studies of ceramide. Topotecan was purchased from Merck (Darmstadt, Germany). RPMI-1640 medium, 3-MA, SP600125 and MDC were purchased from Sigma Co.
Cell lines, cell culture and cell death assay Human nasopharyngeal carcinoma cell line CNE2 and hepatocellular carcinoma cell line Hep3B were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, penicillin (50 U/ml) and streptomycin (50 mg/ml). For cell death assay, cells were plated in 24-well culture plates and allowed to adhere overnight. Ceramide was added at the indicated concentrations. Cells were incubated for 24 h under the described conditions and stained with the vital dye trypan blue (Sigma). All the unstained or stained cells were counted.
Annexin V-fluorescein isothiocyanate/propidium iodide staining Annexin V-fluorescein isothiocyanate/propidium iodide staining was performed using the annexin V-fluorescein isothiocyanate Apoptosis detection kit (Calbiochem) according to the manufacturer's instruction. Apoptosis was analysed by flow cytometry (Beckman Coulter, Fullerton, CA, USA) at a wavelength of 488 nm immediately.
Confocal microscopy
Cells were plated at 50% confluence on glass coverslips and treated with 20 mM ceramide or dimethyl sulphoxide for 24 h. Thereafter, the cells were incubated with 0.05 mM MDC or 1 mg/ ml acridine orange (Sigma) for 15 min, fixed for 30 min at room temperature 37 1C in 3.7% paraformaldehyde in phosphatebuffered saline, rinsed and dried. Cells were observed at Â 60 magnification using an Olympus FV-1000 Confocal microscope.
Indirect immunofluorescence CNE2 and Hep3B cells were grown on glass coverslips. After tumour cells were treated as described earlier, the cells were fixed with 3.7% paraformaldehyde (in phosphate-buffered saline) for 30 min at room temperature. After sequential treatment with NH 4 Cl (50 mM in 20 mM glycine), Triton X-100 (0.1% in phosphate-buffered saline) for 10 min and bovine serum albumin (1% in phosphate-buffered saline) for 1 h at room temperature, anti-MAP-LC3 antibody (Santa Cruz Biotechnology, Inc., California, CA, USA: sc-28266) (1:200 in bovine serum albumin) was added and incubated for 2 h at room temperature. After an additional incubation for 1 h at room temperature with fluorescein isothiocyanate-conjugated secondary antibody (Santa Cruz Biotechnology, Inc.) (1:100 in bovine serum albumin), the slides were mounted in antifading solution (Permafluor, Beckman Coulter, Krefeld, Germany) and stored at 4 1C. Confocal laser-scanning microscopy was carried out.
Reverse transcription PCR Total RNA was isolated by TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Reverse transcription PCR was performed as described earlier Liu et al., 2007) .
To detect the mRNA of the Beclin 1 (GenBank accession number NM003766.2), PCR primers were employed, which are as follows: forward primer: 5 0 -AAGACAGAGC-GATG GTAG-3 0 and reverse primer: 5 0 -CTGGGCTGTGGTAAG TAA-3 0 . These primers for Beclin 1 were designed to generate a fragment of 282 bp. The forward primer (5 0 -CCACCCATGG CAAATTCCATGGCA-3 0 ) and the reverse primer (5 0 -TCTA GACGGCAGGTCAGGTCCACC-3 0 ) were used to generate a 588 bp fragment of glyceraldehyde 3-phosphate dehydrogenase (GenBank accession number NM002046.3) as internal control.
Immunoblotting analysis
Protein extraction and immunoblotting were performed as described earlier (Zhu et al., 2005; Zhou et al., 2006) . The following primary antibodies were used: c-Jun (H-79) antibody (sc-1694), p-c-Jun (KM-1) antibody (sc-822), glyceraldehyde 3-phosphate dehydrogenase antibody (sc-47724) and horseradish peroxidase-conjugated secondary antibody, which were purchased from Santa Cruz Biotechnology, Inc. SAPK/JNK antibody (no. 9252), Phospho-SAPK/JNK (Thr183/Tyr185) antibody (no. 9251), Beclin 1 antibody (no. 3738) and ECL chemiluminescence reagents were obtained from Cell Signaling (Beverly, MA, USA). Anti-LC3 antibody (nos. 0231-100 and NB100-2220) was obtained from nanotools GmbH (Munich, Germany) and Novus Biologicals Inc. (Littleton, CO, USA).
siRNA transfection
The target sequence for JNK1/2-specific siRNA was 5 0 -AAAA AGAAUGUCCUACCUUCU-3 0 (GeneBank accession number NM002750.2) (Gururajan et al., 2005) , c-Jun-specific siRNA sequence was 5 0 -AGAUGGAAACGACCUUCUA TT-3 0 (GeneBank accession number NM002228.3), the target sequences for Beclin 1-specific siRNAs were 5 0 -UGGAAUGG AAUGAGAUUAATT-3 0 and 5 0 -GCUCAGUAUCAG AGA GAAUTT-3 0 (GeneBank accession number NM003766.2), all of which and the control siRNA (no silencing) were synthesized by GenChem Co. (Shanghai, China). Transfection was performed as described earlier Liu et al., 2007) .
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed using the ChIP assay kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instruction. Approximately 1 Â 10 7 cancer cells were used in each treatment. c-Jun antibody (sc-1694) and rabbit normal IgG were purchased from Santa Cruz. PCR amplification was performed using the primers spanning the c-Jun site on beclin 1 promoter, which are forward 5 0 -AAGCTGGGATTATAGGCG-3 0 and reverse 5 0 -CCACGGGAAGTGTAGGAG-3 0 .
Reporter construction and luciferase assays A fragment spanning from À2072 to þ 173 relative to the transcription start site of human beclin 1 genomic sequence was produced by PCR with the forward primer 5 0 -AGGCAAT ATGAAAACAGGC-3 0 and the reverse primer 5 0 -GGGA AGGGACTCCAATAAG-3 0 . This fragment was fused to the firefly luciferase gene of pGL3-Basic vector (Promega Co., Madison, WI, USA) to generate a beclin 1 (À2072/ þ 173)-luc. The luciferase reporter constructs with double c-Jun-bindingconserved sequence (5 0 -tcctgacctcacgttcctgacctcacgt-3 0 ) from the promoter of beclin 1 and its mutant (5 0 -tccgaacctcgcgttcc gaacctcgcgt-3 0 ) were constructed. The PCR products were subcloned into the MluI and XhoI sites of pGL3-Basic. The constructs were confirmed by DNA sequencing. Cells were transfected with 1 mg of various reporter plasmids or pGL3-Basic vector, and 10 ng of pRL-TK luciferase reporter plasmid. Cancer cells were kept in medium after transfection for 36 h, and then treated with or without ceramide for 12 h. The levels of firefly luciferase activity were normalized to pRL-TK luciferase activity. quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene 25: 503-511. Zhu XF, Xie BF, Zhou JM, Feng GK, Liu ZC, Wei XY et al. (2005) .
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